{
    "id": 2931,
    "fullName": "RAD52 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type RAD52 indicates that no mutation has been detected within the RAD52 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5893,
        "geneSymbol": "RAD52",
        "terms": [
            "RAD52"
        ]
    },
    "variant": "wild-type",
    "createDate": "01/13/2015",
    "updateDate": "10/07/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1613,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "RAD52 is proposed to act redundantly to the BRCA1-BRCA2-PALB2 pathway in homologous recombination (PMID: 22964643). Breast cancer cells harboring a BRCA1 inactivating mutation were sensitive to an aptamer targeting Rad52, in contrast with cells with wild-type BRCA1, suggesting that Rad52 is a promising therapeutic target for inducing synthetic lethality in BRCA1-deficient cells (PMID: 23836560).",
            "molecularProfile": {
                "id": 2754,
                "profileName": "BRCA1 inact mut RAD52 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1662,
                    "pubMedId": 22964643,
                    "title": "RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22964643"
                },
                {
                    "id": 1666,
                    "pubMedId": 23836560,
                    "title": "Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836560"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1615,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "RAD52 is proposed to act redundantly to the BRCA1-BRCA2-PALB2 pathway in homologous recombination (PMID: 22964643). Pancreatic cancer cells with a BRCA2 inactivating mutation were sensitive to an aptamer targeting Rad52, in contrast with cells with wild-type BRCA2, suggesting that Rad52 is a promising therapeutic target for inducing synthetic lethality in BRCA2-deficient cells (PMID: 23836560).",
            "molecularProfile": {
                "id": 2756,
                "profileName": "BRCA2 inact mut RAD52 wild-type"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1662,
                    "pubMedId": 22964643,
                    "title": "RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22964643"
                },
                {
                    "id": 1666,
                    "pubMedId": 23836560,
                    "title": "Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23836560"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2753,
            "profileName": "RAD52 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2754,
            "profileName": "BRCA1 inact mut RAD52 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2756,
            "profileName": "BRCA2 inact mut RAD52 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}